Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340234 · ClinicalTrials.gov registry record · Phase 2
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT02340234 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 212 participants.
The verdict
NCT02340234, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical corticosteroids (TCS). The study includes a screening visit, a 2-week run-in period, a 12-week blinded treatment period, and an 8-week safety follow-up period. Following screening visit, eligible participants will enter in run-in period (Days - 14 to - 1) during which a protocol-specified topical therapy regimen will be initiated. At the end of the run-in period, participants who have: 1) demonstrated compliance with the protocol-specified TCS regimen, and 2) who continue to fulfill the eligibility criteria will be randomized.
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG TCS Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340234
The ClinicalTrials.gov registry entry for NCT02340234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02340234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340234 about?
NCT02340234 is a clinical study titled "A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis". This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical corticosteroids (TCS). The study i...
What is the current status of trial NCT02340234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2015-05. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02340234?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), TCS Cream (DRUG).
Who is sponsoring clinical trial NCT02340234?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.